Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTB-09
- Development stage
- Preclinical
- Lead developer
- Next Innovative Therapeutics
- Administration
- Oral
01
Overview
PTB-09 (also known as PBTX-09) is a preclinical-stage nutraceutical candidate developed by Next Innovative Therapeutics (Nintx). It is designed to modulate the microbiome gut-skin axis to address skin health. Developed using Nintx's proprietary GAIApath® and xGIbiomics® platforms, which leverage Brazil's rich biodiversity to identify plant-based natural products, PTB-09 aims to influence skin conditions indirectly by targeting and balancing the gut microbiome. The candidate is currently in preclinical development, with clinical evaluation projected to begin around 2027.
Beyond the preview
Go deeper on PTB-09.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTB-09.